These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16040258)

  • 21. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes.
    Andrieux L; Langouët S; Fautrel A; Ezan F; Krauser JA; Savouret JF; Guengerich FP; Baffet G; Guillouzo A
    Mol Pharmacol; 2004 Apr; 65(4):934-43. PubMed ID: 15044623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/1st communication: The contribution of clinical pharmacology].
    Kuhlmann J
    Arzneimittelforschung; 2004; 54(5):251-8. PubMed ID: 15212186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets.
    Vogt A; Lazo JS
    Pharmacol Ther; 2005 Aug; 107(2):212-21. PubMed ID: 15925410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The upregulation of heat shock protein 47 in human gingival fibroblasts stimulated with cyclosporine A.
    Chang TY; Tsai CH; Chang YC
    J Periodontal Res; 2010 Jun; 45(3):317-22. PubMed ID: 19909402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of endothelial nitric oxide synthase: involvement of protein kinase G 1 beta, serine 116 phosphorylation and lipid structures.
    John TA; Ibe BO; Raj JU
    Clin Exp Pharmacol Physiol; 2008 Feb; 35(2):148-58. PubMed ID: 17892503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity.
    Martin E; Mukherjee P; Sullivan D; Jansen J
    J Chem Inf Model; 2011 Aug; 51(8):1942-56. PubMed ID: 21667971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Classification of kinase inhibitors using a Bayesian model.
    Xia X; Maliski EG; Gallant P; Rogers D
    J Med Chem; 2004 Aug; 47(18):4463-70. PubMed ID: 15317458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century.
    Kenakin T; Bylund DB; Toews ML; Mullane K; Winquist RJ; Williams M
    Biochem Pharmacol; 2014 Jan; 87(1):64-77. PubMed ID: 24269285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity.
    Kostadinova R; Boess F; Applegate D; Suter L; Weiser T; Singer T; Naughton B; Roth A
    Toxicol Appl Pharmacol; 2013 Apr; 268(1):1-16. PubMed ID: 23352505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates.
    Guenat S; Rouleau N; Bielmann C; Bedard J; Maurer F; Allaman-Pillet N; Nicod P; Bielefeld-Sévigny M; Beckmann JS; Bonny C; Bossé R; Roduit R
    J Biomol Screen; 2006 Dec; 11(8):1015-26. PubMed ID: 17092917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds.
    Wolfe A; O'Clair B; Groppi VE; McEwen DP
    J Biomol Screen; 2013 Dec; 18(10):1234-45. PubMed ID: 24019254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection criteria for drug-like compounds.
    Muegge I
    Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flow cytometry in preclinical drug development.
    Lappin PB
    Methods Mol Biol; 2010; 598():303-21. PubMed ID: 19967522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classification of compounds with distinct or overlapping multi-target activities and diverse molecular mechanisms using emerging chemical patterns.
    Namasivayam V; Hu Y; Balfer J; Bajorath J
    J Chem Inf Model; 2013 Jun; 53(6):1272-81. PubMed ID: 23692475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.
    Berg EL; Polokoff MA; O'Mahony A; Nguyen D; Li X
    Int J Mol Sci; 2015 Jan; 16(1):1008-29. PubMed ID: 25569083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.
    Parsons AB; Lopez A; Givoni IE; Williams DE; Gray CA; Porter J; Chua G; Sopko R; Brost RL; Ho CH; Wang J; Ketela T; Brenner C; Brill JA; Fernandez GE; Lorenz TC; Payne GS; Ishihara S; Ohya Y; Andrews B; Hughes TR; Frey BJ; Graham TR; Andersen RJ; Boone C
    Cell; 2006 Aug; 126(3):611-25. PubMed ID: 16901791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.